Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization

Abstract

Purpose

To assess the 5-year visual outcome of intravitreal bevacizumab in inflammatory ocular neovascularization.

Methods

Retrospective, multicenter, consecutive case series of eight patients with inflammatory ocular neovascularization refractory to standard therapy who were treated with intravitreal bevacizumab and followed for 5 years after first injection. The outcome measures included improvement of best-corrected visual acuity expressed as logarithm of minimum angle of resolution.

Results

Mean best-corrected visual acuity significantly improved from 0.58 at baseline (6/23 or 20/76; standard deviation = 0.32) to 0.20 at final assessment (6/10 or 20/32; standard deviation = 0.25) (n = 8; P = 0.02), a gain of 3.8 lines (median: three injections; eight eyes; eight patients). No ocular or systemic complications from intravitreal bevacizumab were noted.

Conclusion

At 5 years, intravitreal bevacizumab sustained significant visual improvement in ocular neovascularization due to a variety of inflammatory ocular diseases without major complications after a median of three injections.

Keywords:

• bevacizumab
• choroidal neovascularization
• punctate inner choroidopathy
• toxoplasmosis
• uveitis
• Vogt-Koyanagi-Harada syndrome

Disclosures

The authors report no conflicts of interest in this work. Institutional Review Board approval of the research was obtained from the American University of Beirut. The study was registered in the National Clinical Trials (NCT00645697).